Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 10/20 | 0.73 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.73 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.73 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.73 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.73 |
| ▸ | ABL1 | P00519 | 11/20 | 0.70 |
| ▸ | BCR | P11274 | 11/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.70 |
| ▸ | PRKCA | P17252 | 6/20 | 0.70 |
| ▸ | SRC | P12931 | 5/20 | 0.70 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | PRKCG | P05129 | 1/20 | 0.69 |
| ▸ | PRKCB | P05771 | 1/20 | 0.69 |
| ▸ | PRKCH | P24723 | 1/20 | 0.69 |
| ▸ | PRKCI | P41743 | 1/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.69 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979760 | 1.00 | PDGFRA (0.73) | PDGFRAMAPK8MAPK9MAPK10IRAK1 | |
| SCHEMBL14979759 | 0.93 | PDGFRA (0.77) | PDGFRAMAPK8MAPK9MAPK10IRAK1 | |
| SCHEMBL14979753 | 0.93 | PDGFRA (0.79) | PDGFRAMAPK8MAPK9MAPK10IRAK1 | |
| SCHEMBL11927817 | 0.85 | PDGFRA (0.92) | PDGFRAMAPK8MAPK9MAPK10ABL1 | |
| SCHEMBL14979770 | 0.85 | PDGFRA (0.82) | PDGFRAMAPK8MAPK9MAPK10ABL1 | |
| SCHEMBL20206264 | 0.85 | IRAK1 (0.68) | PDGFRAMAPK8MAPK9MAPK10IRAK1 | |
| SCHEMBL14979762 | 0.85 | EGFR (0.77) | PDGFRAMAPK8MAPK9MAPK10IRAK1 | |
| SCHEMBL14979754 | 0.85 | BTK (0.56) | PDGFRAMAPK8MAPK9MAPK10IRAK1 | |
| SCHEMBL14979769 | 0.85 | ABL1 (0.70) | PDGFRAMAPK8MAPK9MAPK10IRAK1 | |
| SCHEMBL29644763 | 0.85 | ABL1 (0.70) | PDGFRAMAPK8MAPK9MAPK10IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182867-A1 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | PEKING UNIVERSITY (CN) | 2024-06-06 | — | — | US | claimed |
| EP-4320223-A1 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | Peking University (CN) | 2024-02-14 | — | — | EP | claimed |
| CN-116981768-A | Reprogramming human somatic chemistry into pluripotent cells | 北京大学 | 2023-10-31 | — | — | CN | claimed |
| WO-2022213731-A1 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | PEKING UNIVERSITY (CN) | 2022-10-13 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12351822-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025069029-A1 | METHODS FOR REJUVENATING HUMAN CELLS | CENTARIX BIOTECH LTD (IL) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240182867-A1 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | PEKING UNIVERSITY (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4320223-A1 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | Peking University (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-20230357714-A1 | STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-11-09 | — | — | US | disclosed |
| CN-116981768-A | Reprogramming human somatic chemistry into pluripotent cells | 北京大学 | 2023-10-31 | — | — | CN | disclosed |
| US-11725185-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2022213731-A1 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | PEKING UNIVERSITY (CN) | 2022-10-13 | — | — | WO | disclosed |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885MAPK8 52/4885MAPK9 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.